Intense pulsed light

Sciton Adds New Dates to Bright Lights Big City Tour

Bright Lights Big City BBL Tour

Laser manufacturer Sciton is extending its Bright Lights Big City BBL Tour hosted by Dr. Patrick Bitter Jr., creator of the Fotofacial. The new 2018 events will start in early June in Fort Lauderdale, followed by Chicago, New York City and Austin, before making a last stop in Washington D.C. in November.

The seminars were created to help clinicians achieve optimal results with the company’s BBL (BroadBand Light), a high energy output intense pulsed light device that offers multiple filters to address a variety of aesthetic concerns.

Rays of Light

Understanding the role of intense pulsed light in today’s aesthetic practices.
Rays of Light

Since it first received U.S. Food and Drug Administration (FDA) approval in 1995, intense pulsed light (IPL) has become one of the most versatile and widely used technologies in aesthetic medicine. It has been used for permanent hair reduction and to treat a variety of concerns, including redness, acne and excess pigmentation. Now that it has been joined by a number of lasers and energy-based devices, the question for providers is: Which patients and indications benefit most from IPL?

Treating PIH With IPL

Treating PIH With IPL

A study published in Dermatologic Surgery (February 2016) examined the safety and efficacy of a novel pulse-in-pulse mode intense pulsed light (IPL) for the treatment of persistent facial post-inflammatory hyperpigmentation (PIH).

IPL May Reduce Acne Breakouts

IPL May Reduce Acne Breakouts

Intense pulsed light treatments increase the expression of transforming growth factor beta1 (TGF-β1) in the skin of patients with mild-to-moderate acne, and this action may help explain its efficacy in reducing acne breakouts. Musheera M Ali, MD, et al, of the Department of Dermatology, School of Medicine, Cardiff University, Cardiff, UK, analyzed biopsies taken from 20 patients at baseline, 48 hours after one IPL treatment and one week following treatment. The biopsies were immunohistochemically analyzed to determine the expression of TGF-β1 and the immunolocalization of Smad3.